Table of contents


On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to David Chaplin, United Kingdom, for 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol (combretastatin A4 phosphate) for the treatment of anaplastic thyroid cancer.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

The sponsorship was transferred to Diamond BioPharm Limited, United Kingdom, in January 2013.

The sponsorship was transferred to Diamond ROC EOOD, Bulgaria, in March 2019.

The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.

This medicine is now known as fosbretabulin tromethamine.

Key facts

Active substance
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine)
Disease / condition
Treatment of anaplastic thyroid cancer
Date of first decision
EU designation number

Sponsor's contact details

Diamond Pharma Services Ireland Limited 
Coliemore House
Coliemore Road
Co. Dublin
Tel. 02039119410

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating